Details of the Drug

General Information of Drug (ID: DM4V6RL)

Drug Name

Ritodrine

Synonyms

Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol

Indication

Disease Entry	ICD 11	Status	REF
Premature labour	JB00	Approved	[1], [2]

Therapeutic Class

Sympathomimetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

287.35

Topological Polar Surface Area (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 31 mL/min/kg [4]
Elimination: 10% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.7 - 2.6 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.9656 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.64% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.4 L/kg [4]

Chemical Identifiers

Formula: C17H21NO3
IUPAC Name: 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
Canonical SMILES: C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O
InChI: InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
InChIKey: IOVGROKTTNBUGK-SJCJKPOMSA-N

Cross-matching ID

PubChem CID: 33572
ChEBI ID: CHEBI:8872
CAS Number: 26652-09-5
DrugBank ID: DB00867
TTD ID: D00LFB
INTEDE ID: DR1429

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Sulfotransferase 1A1 (SULT1A1)_{Main DME}	DEYWLRK	ST1A1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Premature labour

ICD Disease Classification

JB00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	4.88E-01	-0.05	-0.12
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	7.10E-01	0.06	0.09
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	3.62E-02	-1.87E-01	-4.46E-01
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	6.72E-01	6.81E-02	1.62E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ritodrine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Ritodrine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[29]
Ivosidenib	DM8S6T7	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[30]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Midostaurin.	Acute myeloid leukaemia [2A60]	[30]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Idarubicin.	Acute myeloid leukaemia [2A60]	[30]
Arn-509	DMT81LZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Arn-509.	Acute myeloid leukaemia [2A60]	[30]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[30]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Oliceridine.	Acute pain [MG31]	[31]
Ivabradine	DM0L594	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ivabradine.	Angina pectoris [BA40]	[30]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Dronedarone.	Angina pectoris [BA40]	[30]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[30]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Cilostazol.	Arterial occlusive disease [BD40]	[30]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Posaconazole.	Aspergillosis [1F20]	[30]
Budesonide	DMJIBAW	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Budesonide.	Asthma [CA23]	[32]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[30]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Ritodrine and Droxidopa.	Autonomic nervous system disorder [8D87]	[33]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Clarithromycin	DM4M1SG	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[30]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Telithromycin	DMZ4P3A	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[31]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Retigabine.	Behcet disease [4A62]	[31]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Eribulin.	Breast cancer [2C60-2C6Y]	[30]
Lapatinib	DM3BH1Y	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lapatinib.	Breast cancer [2C60-2C6Y]	[30]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Bosutinib.	Breast cancer [2C60-2C6Y]	[30]
Corticotropin	DMP9TWZ	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Corticotropin.	Chronic kidney disease [GB61]	[32]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[30]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Ritodrine and Levomilnacipran.	Chronic pain [MG30]	[34]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Halothane.	Corneal disease [9A76-9A78]	[30]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Sevoflurane.	Corneal disease [9A76-9A78]	[30]
Pasireotide	DMHM7JS	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Pasireotide.	Cushing syndrome [5A70]	[30]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Osilodrostat.	Cushing syndrome [5A70]	[31]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Ritodrine and Selegiline.	Depression [6A70-6A7Z]	[29]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Ritodrine and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Ritodrine and Milnacipran.	Depression [6A70-6A7Z]	[34]
Escitalopram	DMFK9HG	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Escitalopram.	Depression [6A70-6A7Z]	[30]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of rapid heart rate by the combination of Ritodrine and Desvenlafaxine.	Depression [6A70-6A7Z]	[34]
Maprotiline	DMPWB7T	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Maprotiline.	Depression [6A70-6A7Z]	[30]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[30]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Deutetrabenazine.	Dystonic disorder [8A02]	[30]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ingrezza.	Dystonic disorder [8A02]	[30]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Solifenacin.	Functional bladder disorder [GC50]	[30]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[30]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Ritodrine and Procarbazine.	Hodgkin lymphoma [2B30]	[29]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Lopinavir	DMITQS0	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Crizotinib.	Lung cancer [2C25]	[30]
Ceritinib	DMB920Z	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ceritinib.	Lung cancer [2C25]	[30]
Osimertinib	DMRJLAT	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Osimertinib.	Lung cancer [2C25]	[30]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Selpercatinib.	Lung cancer [2C25]	[30]
Lumefantrine	DM29GAD	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lumefantrine.	Malaria [1F40-1F45]	[30]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Hydroxychloroquine.	Malaria [1F40-1F45]	[30]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Primaquine.	Malaria [1F40-1F45]	[30]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[30]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[30]
Vemurafenib	DM62UG5	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Vemurafenib.	Melanoma [2C30]	[30]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and LGX818.	Melanoma [2C30]	[30]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Panobinostat.	Multiple myeloma [2A83]	[30]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Fingolimod.	Multiple sclerosis [8A40]	[30]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Ozanimod.	Multiple sclerosis [8A40]	[35]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Romidepsin.	Mycosis fungoides [2B01]	[31]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[30]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[30]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Promethazine.	Nausea/vomiting [MD90]	[30]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Ondansetron.	Nausea/vomiting [MD90]	[30]
Sibutramine	DMFJTDI	Moderate	Additive hypertensive effects by the combination of Ritodrine and Sibutramine.	Obesity [5B80-5B81]	[36]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Lofexidine.	Opioid use disorder [6C43]	[30]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Rucaparib.	Ovarian cancer [2C73]	[30]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Buprenorphine.	Pain [MG30-MG3Z]	[30]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Triclabendazole.	Parasitic worm infestation [1F90]	[31]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Ritodrine and Safinamide.	Parkinsonism [8A00]	[29]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Ritodrine and Rasagiline.	Parkinsonism [8A00]	[29]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Pimavanserin.	Parkinsonism [8A00]	[30]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Famotidine.	Peptic ulcer [DA61]	[37]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[38]
Lefamulin	DME6G97	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Lefamulin.	Pneumonia [CA40]	[30]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Degarelix.	Prostate cancer [2C82]	[30]
ABIRATERONE	DM8V75C	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and ABIRATERONE.	Prostate cancer [2C82]	[30]
Enzalutamide	DMGL19D	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Enzalutamide.	Prostate cancer [2C82]	[30]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[30]
Ciclesonide	DM2NA4K	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[32]
Dexamethasone	DMMWZET	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Dexamethasone.	Rheumatoid arthritis [FA20]	[32]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Quetiapine.	Schizophrenia [6A20]	[30]
Mesoridazine	DM2ZGAN	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Mesoridazine.	Schizophrenia [6A20]	[30]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Aripiprazole.	Schizophrenia [6A20]	[37]
Iloperidone	DM6AUFY	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Iloperidone.	Schizophrenia [6A20]	[30]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Paliperidone.	Schizophrenia [6A20]	[30]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Amisulpride.	Schizophrenia [6A20]	[30]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Asenapine.	Schizophrenia [6A20]	[30]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Pimozide.	Schizophrenia [6A20]	[30]
Methylprednisolone	DM4BDON	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[32]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ritodrine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[39]
Vandetanib	DMRICNP	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[30]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[30]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[30]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Pitolisant.	Somnolence [MG42]	[30]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[30]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Ritodrine and Lenvatinib.	Thyroid cancer [2D10]	[30]
Cabozantinib	DMIYDT4	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Cabozantinib.	Thyroid cancer [2D10]	[30]
Fluticasone	DMGCSVF	Minor	Increased risk of hypokalemia by the combination of Ritodrine and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[32]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Ritodrine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[30]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[30]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[30]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Ritodrine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[30]
-----------


⏷ Show the Full List of 105 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7294).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071438.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res. 2005 Aug;22(8):1406-10.
9	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
10	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
11	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
12	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
13	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
14	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
15	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
16	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
17	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
18	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
19	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
20	Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
21	Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
22	Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
23	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
24	Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
25	Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
26	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
27	Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
29	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
30	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
32	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
33	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
34	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
35	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
36	Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
37	Cerner Multum, Inc. "Australian Product Information.".
38	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
39	Canadian Pharmacists Association.